Trade Mark Journal No.2026/019 8 May 2026
WO0000001914516 (5)
Office of origin: United States of America
Date of International Registration:5 March 2026
Date of designation in the UK:
5 March 2026
- Class 5
- Pharmaceutical preparations for alleviating side effects of cancer treatments; pharmaceutical preparations for alleviating side effects of chemotherapy; pharmaceutical preparations for alleviating side effects of radiation therapy; pharmaceutical preparations for alleviating side effects of targeted cancer treatments; pharmaceutical preparations for alleviating side effects of targeted cancer treatments, namely, tyrosine kinase inhibitors; pharmaceutical preparations for alleviating side effects of immunotherapy treatments; pharmaceutical preparations for alleviating gastrointestinal distress, mucocitis, nausea, vomiting and diarrhea; pharmaceutical preparations for stimulating appetite; pharmaceutical preparations for preventing weight loss; pharmaceutical preparations for protecting bone marrow and the production of bone marrow; pharmaceutical preparations for protecting stem cells and stimulating the production of stem cells; pharmaceutical preparations for increasing resiliency of stem cells, increasing the number of stem cells, and preventing the reduction of stem cell populations; pharmaceutical preparations for protecting blood cells, alleviating anemia, neutropenia, thrombocytopenia, and alleviating low blood counts; pharmaceutical preparations for alleviating dose limiting side effects of cancer treatments, chemotherapy, radiation therapy, targeted cancer treatments and immunotherapy treatments; pharmaceutical preparations for the prevention and treatment of side effects of cancer treatments; pharmaceutical preparations for the prevention and treatment of side effects of chemotherapy; pharmaceutical preparations for the prevention and treatment of side effects of radiation therapy; pharmaceutical preparations for the prevention and treatment of side effects of targeted cancer treatments; pharmaceutical preparations for the prevention and treatment of side effects of targeted cancer treatments, namely, tyrosine kinase inhibitors; pharmaceutical preparations for the prevention and treatment of side effects of immunotherapy treatments; pharmaceutical preparations for the prevention and treatment of gastrointestinal distress, mucocitis, nausea, vomiting and diarrhea; pharmaceutical preparations for the prevention and treatment of loss of appetite; pharmaceutical preparations for the prevention and treatment of weight loss; pharmaceutical preparations for the treatment and prevention of bone marrow damage; pharmaceutical preparations for the treatment and prevention of stem cell damage and reduction of stem cell populations; pharmaceutical preparations for the treatment and prevention of blood cell damage, anemia, and low blood count; pharmaceutical preparations for the treatment and prevention of dose limiting side effects of cancer treatments, chemotherapy, radiation therapy, targeted cancer treatments and immunotherapy treatments; pharmaceutical preparations for the treatment and prevention of side effects of cancer treatments, chemotherapy, radiation therapy, targeted cancer treatments and immunotherapy treatments, namely, reduced fertility; pharmaceutical preparations for supporting stem cell health and production; pharmaceutical preparations for supporting stem cell health and production, namely for stimulating uterine, bone marrow and gastrointestinal track stem cell production; pharmaceutical preparations for the treatment of radiation exposure; pharmaceutical preparations for the treatment of cancer; pharmaceutical preparations for the treatment of inflammatory bowel disease, ulcerative colitis and other inflammatory bowel disorders; pharmaceutical preparations for the enhancement of chemotherapy; pharmaceutical preparations for the enhancement of immunotherapy; fertility enhancement preparations.
Caper Labs, Inc.
Representative: Isaac M. Fine KPPB LLP, 180 E. Ocean Blvd., Suite 1030, Long Beach CA 90802, UNITED STATES OF AMERICA